Literature DB >> 27362845

Preliminary differences in resting state MEG functional connectivity pre- and post-ketamine in major depressive disorder.

Allison C Nugent1, Stephen E Robinson2, Richard Coppola2, Carlos A Zarate3.   

Abstract

Functional neuroimaging techniques including magnetoencephalography (MEG) have demonstrated that the brain is organized into networks displaying correlated activity. Group connectivity differences between healthy controls and participants with major depressive disorder (MDD) can be detected using temporal independent components analysis (ICA) on beta-bandpass filtered Hilbert envelope MEG data. However, the response of these networks to treatment is unknown. Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, exerts rapid antidepressant effects. We obtained MEG recordings before and after open-label infusion of 0.5mg/kg ketamine in MDD subjects (N=13) and examined networks previously shown to differ between healthy individuals and those with MDD. Connectivity between the amygdala and an insulo-temporal component decreased post-ketamine in MDD subjects towards that observed in control subjects at baseline. Decreased baseline connectivity of the subgenual anterior cingulate cortex (sgACC) with a bilateral precentral network had previously been observed in MDD compared to healthy controls, and the change in connectivity post-ketamine was proportional to the change in sgACC glucose metabolism in a subset (N=8) of subjects receiving [11F]FDG-PET imaging. Ketamine appeared to reduce connectivity, regardless of whether connectivity was abnormally high or low compared to controls at baseline. These preliminary findings suggest that sgACC connectivity may be directly related to glutamate levels. Published by Elsevier Ireland Ltd.

Entities:  

Keywords:  Connectivity; Depression; Independent components analysis (ICA); Ketamine; Magnetoencephalography (MEG); Resting state

Mesh:

Substances:

Year:  2016        PMID: 27362845      PMCID: PMC4992587          DOI: 10.1016/j.pscychresns.2016.06.006

Source DB:  PubMed          Journal:  Psychiatry Res Neuroimaging        ISSN: 0925-4927            Impact factor:   2.376


  65 in total

Review 1.  The gamma cycle.

Authors:  Pascal Fries; Danko Nikolić; Wolf Singer
Journal:  Trends Neurosci       Date:  2007-06-06       Impact factor: 13.837

Review 2.  A systematic review of relations between resting-state functional-MRI and treatment response in major depressive disorder.

Authors:  Gabriel S Dichter; Devin Gibbs; Moria J Smoski
Journal:  J Affect Disord       Date:  2014-09-26       Impact factor: 4.839

Review 3.  Signaling pathways underlying the rapid antidepressant actions of ketamine.

Authors:  Ronald S Duman; Nanxin Li; Rong-Jian Liu; Vanja Duric; George Aghajanian
Journal:  Neuropharmacology       Date:  2011-09-02       Impact factor: 5.250

Review 4.  Imaging phenotypes of major depressive disorder: genetic correlates.

Authors:  J B Savitz; W C Drevets
Journal:  Neuroscience       Date:  2009-04-07       Impact factor: 3.590

5.  Abnormal resting-state cerebellar-cerebral functional connectivity in treatment-resistant depression and treatment sensitive depression.

Authors:  Wenbin Guo; Feng Liu; Zhimin Xue; Keming Gao; Zhening Liu; Changqing Xiao; Huafu Chen; Jingping Zhao
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2013-01-23       Impact factor: 5.067

Review 6.  Models and mechanisms of anxiety: evidence from startle studies.

Authors:  Christian Grillon
Journal:  Psychopharmacology (Berl)       Date:  2007-12-06       Impact factor: 4.530

7.  Gamma rhythms and beta rhythms have different synchronization properties.

Authors:  N Kopell; G B Ermentrout; M A Whittington; R D Traub
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

8.  Glutamatergic and resting-state functional connectivity correlates of severity in major depression - the role of pregenual anterior cingulate cortex and anterior insula.

Authors:  Dorothea I Horn; Chunshui Yu; Johann Steiner; Julia Buchmann; Joern Kaufmann; Annemarie Osoba; Ulf Eckert; Kathrin C Zierhut; Kolja Schiltz; Huiguang He; Bharat Biswal; Bernhard Bogerts; Martin Walter
Journal:  Front Syst Neurosci       Date:  2010-07-15

9.  Ketamine decreases resting state functional network connectivity in healthy subjects: implications for antidepressant drug action.

Authors:  Milan Scheidegger; Martin Walter; Mick Lehmann; Coraline Metzger; Simone Grimm; Heinz Boeker; Peter Boesiger; Anke Henning; Erich Seifritz
Journal:  PLoS One       Date:  2012-09-24       Impact factor: 3.240

10.  Relationship of resting brain hyperconnectivity and schizophrenia-like symptoms produced by the NMDA receptor antagonist ketamine in humans.

Authors:  N R Driesen; G McCarthy; Z Bhagwagar; M Bloch; V Calhoun; D C D'Souza; R Gueorguieva; G He; R Ramachandran; R F Suckow; A Anticevic; P T Morgan; J H Krystal
Journal:  Mol Psychiatry       Date:  2013-01-22       Impact factor: 15.992

View more
  15 in total

Review 1.  Ketamine-Associated Brain Changes: A Review of the Neuroimaging Literature.

Authors:  Dawn F Ionescu; Julia M Felicione; Aishwarya Gosai; Cristina Cusin; Philip Shin; Benjamin G Shapero; Thilo Deckersbach
Journal:  Harv Rev Psychiatry       Date:  2018 Nov/Dec       Impact factor: 3.732

2.  Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression.

Authors:  Mark J Niciu; Bridget J Shovestul; Brittany A Jaso; Cristan Farmer; David A Luckenbaugh; Nancy E Brutsche; Lawrence T Park; Elizabeth D Ballard; Carlos A Zarate
Journal:  J Affect Disord       Date:  2018-02-17       Impact factor: 4.839

Review 3.  Leveraging Neuroplasticity to Enhance Adaptive Learning: The Potential for Synergistic Somatic-Behavioral Treatment Combinations to Improve Clinical Outcomes in Depression.

Authors:  Samuel T Wilkinson; Paul E Holtzheimer; Shan Gao; David S Kirwin; Rebecca B Price
Journal:  Biol Psychiatry       Date:  2018-09-20       Impact factor: 13.382

Review 4.  Intrinsic Connectivity Networks of Glutamate-Mediated Antidepressant Response: A Neuroimaging Review.

Authors:  Ilya Demchenko; Vanessa K Tassone; Sidney H Kennedy; Katharine Dunlop; Venkat Bhat
Journal:  Front Psychiatry       Date:  2022-05-26       Impact factor: 5.435

Review 5.  Neurobiological biomarkers of response to ketamine.

Authors:  Bashkim Kadriu; Elizabeth D Ballard; Ioline D Henter; Stephen Murata; Nimesha Gerlus; Carlos A Zarate
Journal:  Adv Pharmacol       Date:  2020-06-18

Review 6.  Alterations of Intrinsic Brain Connectivity Patterns in Depression and Bipolar Disorders: A Critical Assessment of Magnetoencephalography-Based Evidence.

Authors:  Golnoush Alamian; Ana-Sofía Hincapié; Etienne Combrisson; Thomas Thiery; Véronique Martel; Dmitrii Althukov; Karim Jerbi
Journal:  Front Psychiatry       Date:  2017-03-17       Impact factor: 4.157

7.  Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression.

Authors:  Wei Guo; Rodrigo Machado-Vieira; Sanjay Mathew; James W Murrough; Dennis S Charney; Matthew Grunebaum; Maria A Oquendo; Bashkim Kadriu; Nirmala Akula; Ioline Henter; Peixiong Yuan; Kathleen Merikangas; Wayne Drevets; Maura Furey; J John Mann; Francis J McMahon; Carlos A Zarate; Yin Yao Shugart
Journal:  Transl Psychiatry       Date:  2018-12-14       Impact factor: 6.222

Review 8.  Biomarkers of ketamine's antidepressant effect: a clinical review of genetics, functional connectivity, and neurophysiology.

Authors:  Alexandra A Alario; Mark J Niciu
Journal:  Chronic Stress (Thousand Oaks)       Date:  2021-05-31

Review 9.  Ketamine: 50 Years of Modulating the Mind.

Authors:  Linda Li; Phillip E Vlisides
Journal:  Front Hum Neurosci       Date:  2016-11-29       Impact factor: 3.169

Review 10.  A Comparison of Neuroimaging Abnormalities in Multiple Sclerosis, Major Depression and Chronic Fatigue Syndrome (Myalgic Encephalomyelitis): is There a Common Cause?

Authors:  Gerwyn Morris; Michael Berk; Basant K Puri
Journal:  Mol Neurobiol       Date:  2017-05-17       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.